论文部分内容阅读
目的探讨胺碘酮与索他洛尔治疗心房颤动患者的成本效果分析。方法特选取2016年1月至2017年1月我院收治的心房颤动患者50例,作为此次研究对象。在患者知情同意的前提下,按照医学分组中常用的随机数字表法将其分成观察组和对照组,每组各25例。对照组患者给予索他洛尔进行治疗,观察组患者给予胺碘酮进行治疗。对比两组患者的用药成本和临床治疗效果。结果对照组患者的用药成本为798.13元,观察组患者的用药成本为2217.14元;对照组患者的治疗有效率为75.1%,观察组患者的治疗有效率为86.2,组间对比差异显著(P<0.05)。结论在对胺碘酮与索他洛尔治疗心房颤动患者的成本效果进行分析后可知,将胺碘酮应用于心房颤动患者的临床治疗中,在治疗有效率上,明显高于索他洛尔,但同时治疗成本也相对较高。
Objective To investigate the cost-effectiveness of amiodarone and sotalol in patients with atrial fibrillation. Methods Select from January 2016 to January 2017 in our hospital admitted to atrial fibrillation in 50 patients, as the study object. On the premise of informed consent, patients were divided into observation group and control group according to the random number table method commonly used in medical grouping, 25 cases in each group. Patients in the control group were treated with sotalol and patients in the observation group were treated with amiodarone. The cost and clinical effect of two groups were compared. Results The cost of medication in the control group was 798.13 yuan and the cost of medication in the observation group was 2217.14 yuan. The effective rate was 75.1% in the control group and 86.2% in the observation group. There was significant difference between the two groups (P < 0.05). Conclusions The analysis of the cost-effectiveness of amiodarone and sotalol in the treatment of atrial fibrillation shows that the clinical efficacy of amiodarone in patients with atrial fibrillation is significantly higher than that of sotalol , But at the same time the cost of treatment is relatively high.